Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BMS SCLC Chances Dive After Opdivo, Yervoy Combo Flunks Checkmate-451

Executive Summary

BMS's Phase III Checkmate-451 combo trial with Opdivo and Yervoy misses its endpoint for small cell lung cancer in overall survival, building on recent disappointment caused by the failure of Checkmate-331.

You may also be interested in...



Accelerated Approval: US FDA Review Of Expedited Program Could Bring More Withdrawals

Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals leads to removal of indications for two PD-1/L-1 inhibitors, AstraZeneca’s Imfinzi and Bristol-Myers Squibb’s Opdivo, both of which had failed confirmatory trials.

AstraZeneca Gets Fast Imfinzi Review For SCLC

The drug major has won a priority review for Imfinzi in small cell lung cancer from the FDA. If approved, the new indication could add $1bn to sales of the checkpoint inhibitor

AstraZeneca Gets Imfinzi Boost From CASPIAN Lung Cancer Trial

Prospects for AstraZeneca’s PD-L1 inhibitor Imfinzi received a welcome boost from an interim analysis of the Phase III study in first-line small-cell lung cancer.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC124235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel